Table 1 Patient characteristics and treatment of the entire cohort
All patients N = 128 (%) | ||
|---|---|---|
Age (mean ± SD, years) | 64.29 ± 9.19 | |
Gender male | 105 (82.0) | |
ECOG | 0 | 63 (50.0) |
1 | 51 (40.5) | |
2 | 11 (8.7) | |
3 | 1 (0.8) | |
Child-Pugh Group | A | 81 (66.4) |
B | 34 (27.9) | |
C | 7 (5.7) | |
ALBI grade | 1 | 23 (25.0) |
2 | 51 (55.4) | |
3 | 18 (19.6) | |
Received prior local therapy | 94 (73.4) | |
Vascular invasion | 41 (32) | |
Dose per fraction | Conventional (180–200 cGy/Fx) | 7 (5.5) |
Hypofractionated (201–500 cGy/Fx) | 79 (61.7) | |
Ultrahypofractionated (501 cGy/Fx≤) | 42 (32.8) | |
Number of fractions | 1–5 | 42 (32.8) |
6–20 | 37 (28.9) | |
> 20 | 49 (38.3) | |
Planned treatment break | 34 (26.6) | |
RT treatment modality | Proton | 36 (28.1) |
GTV volume (median, Q1, Q3 cm³) | 113, 53, 282 | |
GTV equivalent sphere diameter (median, Q1, Q3 cm) | 6.0, 4.6, 8.1 | |
BED10 (median, Q1, Q3, Gy) | 78, 69, 98 | |
Survival (median, months) | 18.31 |